Pasar al contenido principal

NUEVAS DIANAS DE INHIBICION DE LA TRANSFORMACION DE ATEROSCLEROSIS SUBCLINICA EN SINDROMES ISQUEMICOS AGUDOS: ANGIOGENESIS MEDIADA POR FACTOR TISULAR

SAF2013-42962-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2013
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario CONSORCI INSTITUT CATALA DE CIENCIES CARDIOVASCULARS DE CIENCIES CARDIOVASCULARS (ICCC)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

mCRP triggers angiogenesis by inducing F3 transcription and TF signalling in microvascular endothelial cells

  • Peña, Esther
  • Torre, Raquel de la
  • Arderiu, Gemma
  • Slevin, Mark
  • Badimón Maestro, Lina
Inflammation contributes to vascular disease progression. However, the role of circulating inflammatory molecules on microvascular endothelial cell (mECs) is not fully elucidated. The aim of this study was to investigate the effects of the short pentraxin CRP on microvascular endothelial cell angiogenic function. Subcutaneously implanted collagen plugs seeded with human mECs exposed to monomeric CRP (mCRP) in mice showed formation of an extended network of microvessels both in the plug and the overlying skin tissue, while mECs exposure to pentameric native CRP (nCRP) induced a much milder effect. To understand the mechanisms behind this angiogenic effects, mECs were exposed to both CRP forms and cell migration, wound repair and tube-like formation were investigated. nCRP effects were moderate and of slow-onset whereas mCRP induced rapid, and highly significant effects. We investigated how circulating nCRP is transformed into mCRP by confocal microscopy and western blot. nCRP is transformed into mCRP on the mECs membranes in a time dependent fashion. This transformation is specific and in part receptor dependent, and the formed mCRP triggers F3 gene transcription and TF-protein expression in mECs to induce angiogenesis. F3-silenced mECs are unable to form angiotubes. In agreement, mCRP induced upregulation of the TF signalling pathway in mECs with downstream phosphorylation of AKT and activation of the transcription factor ETS1 leading to increased CCL2 release. The circulating pentraxin nCRP with little pro-angiogenic effect when dissociated into mCRP on the surface of mECs is able to trigger potent proangiogenic effects by inducing F3-gene upregulation and TF signalling., This work was supported by Spanish Ministry of Science Plan Estatal I+D+I 2013–2016 [SAF2013–42962-R to LB] cofunded by Fondo Europeo de Desarrollo Regional (FEDER-“Una manera de hacer Europa”), Red de Terapia Celular [RD/12/0019/0026 to LB] and Red Investigación Cardiovascular [RD/12/00420027 to LB] (CPII13/00012, PI12/02332 to GA) from Instituto Salud Carlos III (ISCIII), Fundación de Investigación Cardiovascular and Fundación Jesus Serra. GA is a Miguel Servet investigator from the Instituto de Salud Carlos III., Peer reviewed
O2, repositorio institucional de la UOC
Publicación Artículo científico (JournalArticle)

Microparticle shedding by erythrocytes, monocytes and vascular smooth muscular cells is reduced by aspirin in diabetic patients, El ácido acetilsalicílico reduce la liberación de micropartículas eritrocitarias, monocitarias y de células del músculo liso vascular en pacientes diabéticos

  • Chiva-Blanch, Gemma
  • Suades Soler, Rosa
  • Padro, Teresa
  • Vilahur, Gemma
  • Peña, Esther
  • Ybarra, Juan
  • Pou Torelló, José María
  • Badimon, Lina
Introduction and objectives. Diabetes mellitus is associated with an enhanced risk for cardiovascular disease and its prevalence is increasing. Diabetes induces metabolic stress on blood and vascular cells, promoting platelet activation and vascular dysfunction. The level of vascular cell activation can be measured by the number and phenotype of microparticles found in the circulation. The aim of this study was to investigate the effect of a platelet-inhibitory dose of aspirin on the number and type of microparticles shed to the circulation. Methods. Forty-three diabetic patients were enrolled in the study and received a daily dose of 100 mg of aspirin for 10 days to cover the average platelet life-span in the circulation. Before and after the intervention period, circulating microparticles were characterized and quantified by flow cytometry. Results. Type 1 diabetic patients had about twice the number of tissue factor-positive circulating microparticles (derived both from platelets and monocytes) and endothelial-derived E-selectin positive microparticles than type 2 diabetic patients. Aspirin therapy significantly inhibited platelets since cyclooxygenase 1 derived thromboxane generation levels were reduced by 99%. Microparticles derived from erythrocytes, activated monocytes, and smooth muscle cells were significantly reduced after 10 days of aspirin administration. Conclusions. These results indicate that: a) vascular and blood cells in type 1 diabetic patients are exposed to more sustained stress shown by their specific microparticle origin and levels; b) aspirin therapy inhibits vascular wall cell activation and microparticle shedding, and c) the effects of aspirin are similar in type 1 and 2 diabetes., Introducción y objetivos. La diabetes mellitus está asociada a mayor riesgo de enfermedad cardiovascular y su prevalencia está en aumento. La diabetes mellitus induce estrés metabólico a las células vasculares, lo cual promueve la activación plaquetaria y la disfunción vascular. El grado de activación de las células vasculares se puede medir con el número y el fenotipo de las micropartículas circulantes. El objetivo de este estudio es investigar el efecto de una dosis de ácido acetilsalicílico con acción inhibidora plaquetaria en el número y el tipo de las micropartículas liberadas a la circulación. Métodos. Se inscribió a 43 pacientes diabéticos que recibieron una dosis diaria de 100 mg de ácido acetilsalicílico durante 10 días, con objeto de cubrir el periodo medio de vida de las plaquetas en la circulación. Antes y después del periodo de intervención, se caracterizaron y cuantificaron las micropartículas circulantes mediante citometría de flujo. Resultados. Respecto a los pacientes con diabetes mellitus tipo 2, aquellos con diabetes mellitus tipo 1 presentaron el doble de micropartículas circulantes positivas para factor tisular (derivadas de plaquetas y monocitos) y micropartículas positivas para selectina E de origen endotelial. El tratamiento con ácido acetilsalicílico inhibió significativamente las plaquetas, puesto que la generación de tromboxano derivado de la ciclooxigenasa 1 disminuyó un 99%. Se produjo una reducción significativa de las micropartículas derivadas de eritrocitos, monocitos activados y células de músculo liso tras 10 días de administración de ácido acetilsalicílico. Conclusiones. Estos resultados indican que: a) las células vasculares y hemáticas de los pacientes con diabetes mellitus tipo 1 están expuestas a un mayor estrés continuo, que se refleja en el origen y la cantidad de sus micropartículas; b) el tratamiento con ácido acetilsalicílico inhibe la activación de las células de la pared vascular y la liberación de micropartículas, y c) los efectos del ácido acetilsalicílico son similares en la diabetes mellitus tipos 1 y 2.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Role of Platelet-Derived Microvesicles As Crosstalk Mediators in Atherothrombosis and Future Pharmacology Targets, A Link between Inflammation, Atherosclerosis, and Thrombosis

  • Badimon, Lina|||0000-0002-9162-2459
  • Suades, Rosa|||0000-0002-0193-3115
  • Fuentes, Eduardo
  • Palomo, Iván
  • Padró, Teresa|||0000-0003-1921-954X
Reports in the last decade have suggested that the role of platelets in atherosclerosis and its thrombotic complications may be mediated, in part, by local secretion of platelet-derived microvesicles (pMVs), small cell blebs released during the platelet activation process. MVs are the most abundant cell-derived microvesicle subtype in the circulation. High concentrations of circulating MVs have been reported in patients with atherosclerosis, acute vascular syndromes, and/or diabetes mellitus, suggesting a potential correlation between the quantity of microvesicles and the clinical severity of the atherosclerotic disease. pMVs are considered to be biomarkers of disease but new information indicates that pMVs are also involved in signaling functions. pMVs evoke or promote haemostatic and inflammatory responses, neovascularization, cell survival, and apoptosis, processes involved in the pathophysiology of cardiovascular disease. This review is focused on the complex cross-talk between platelet-derived microvesicles, inflammatory cells and vascular elements and their relevance in the development of the atherosclerotic disease and its clinical outcomes, providing an updated state-of-the art of pMV involvement in atherothrombosis and pMV potential use as therapeutic agent influencing cardiovascular biomedicine in the future.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Macrophages of genetically characterized familial hypercholesterolaemia patients show up-regulation of LDL-receptor-related proteins

  • Escate, Rafael|||0000-0002-8448-7244
  • Padró, Teresa|||0000-0003-1921-954X
  • Borrell-Pages, Maria|||0000-0002-1759-9756
  • Suades, Rosa|||0000-0002-0193-3115
  • Aledo, Rosa
  • Mata, Pedro
  • Badimon, Lina|||0000-0002-9162-2459
Familial hypercholesterolaemia (FH) is a major risk for premature coronary heart disease due to severe long-life exposure to high LDL levels. Accumulation of LDL in the vascular wall triggers atherosclerosis with activation of the innate immunity system. Here, we have investigated (i) gene expression of LDLR and LRPs in peripheral blood cells (PBLs) and in differentiated macrophages of young FH-patients; and (ii) whether macrophage from FH patients have a differential response when exposed to high levels of atherogenic LDL. PBLs in young heterozygous genetically characterized FH patients have higher expression of LRP5 and LRP6 than age-matched healthy controls or patients with secondary hypercholesterolaemia. LRP1 levels were similar among groups. In monocyte-derived macrophages (MACs), LRP5 and LRP1 transcript levels did not differ between FHs and controls in resting conditions, but when exposed to agLDL, FH-MAC showed a highly significant up-regulation of LRP5, while LRP1 was unaffected. PBL and MAC cells from FH patients had significantly lower LDLR expression than control cells, independently of the lipid-lowering therapy. Furthermore, exposure of FH-MAC to agLDL resulted in a reduced expression of CD163, scavenger receptor with anti-inflammatory and atheroprotective properties. In summary, our results show for first time that LRPs, active lipid-internalizing receptors, are up-regulated in innate immunity cells of young FH patients that have functional LDLR mutations. Additionally, their reduced CD163 expression indicates less atheroprotection. Both mechanisms may play a synergic effect on the onset of premature atherosclerosis in FH patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

ApoL1 levels in high density lipoprotein and cardiovascular event presentation in patients with familial hypercholesterolemia

  • Cubedo, Judit|||0000-0003-3291-9137
  • Padró, Teresa|||0000-0003-1921-954X
  • Alonso Karlezi, Rodrigo|||0000-0002-8119-1245
  • Mata, Pedro
  • Badimon, Lina|||0000-0002-9162-2459
HDL composition rather than HDL-cholesterol (HDL-C) levels seems to be a key determinant of HDL-induced atheroprotection. Heterozygous familial hypercholesterolemia (FH) patients, with lifelong exposure to high LDL levels, show a high prevalence of premature coronary artery disease. We hypothesized that HDL of FH patients might have a modified protein composition and investigated the proteomic signature of HDL obtained from FH patients and their unaffected relatives. HDLs were characterized by 2D electrophoresis/MS in 10 families from the SAFEHEART cohort (3 individuals/family: 2 with genetic FH diagnosis and 1 non-FH relative) clinically characterized and treated as per guidelines. FH patients had lower apoA-I levels and a differential HDL distribution profile of apoL1 and apoA-IV. ELISA validation revealed decreased apoL1 serum levels in FH patients. ApoL1 levels were able to predict presentation of an ischemic cardiac event, and apoL1/HDL-C ratio was associated with the survival rate after the event. FH patients who died because of a fatal cardiac event had lower apoL1 and LCAT content in HDL3 an average of 3.5 years before the event than those who survived. Changes in HDL protein composition could affect patients prognosis. The proteomic profile of apoL1 is modified in HDLs of high cardiovascular risk patients, and apoL1 plasma levels are significantly lower in serum and in HDL3 of patients that will suffer an adverse cardiac event within 3 years. Cubedo, J., T. Padr, R. Alonso, P. Mata, and L. Badimon. ApoL1 levels in high density lipoprotein and cardiovascular event presentation in patients with familial hypercholesterolemia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A comprehensive study on different modelling approaches to predict platelet deposition rates in a perfusion chamber

  • Pallarès, Jordi
  • Senan, Oriol
  • Guimerà, Roger
  • Vernet, Anton|||0000-0002-7028-1368
  • Aguilar Mogas, Antoni|||0000-0002-5952-3629
  • Vilahur, Gemma|||0000-0002-2828-8873
  • Badimon, Lina|||0000-0002-9162-2459
  • Sales-Pardo, Marta
  • Cito, Salvatore
Thrombus formation is a multiscale phenomenon triggered by platelet deposition over a protrombotic surface (eg. a ruptured atherosclerotic plaque). Despite the medical urgency for computational tools that aid in the early diagnosis of thrombotic events, the integration of computational models of thrombus formation at different scales requires a comprehensive understanding of the role and limitation of each modelling approach. We propose three different modelling approaches to predict platelet deposition. Specifically, we consider measurements of platelet deposition under blood flow conditions in a perfusion chamber for different time periods (3, 5, 10, 20 and 30 minutes) at shear rates of 212 s<sup.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A novel truncated form of apolipoprotein A-I transported by dense LDL is increased in diabetic patients

  • Cubedo, Judit|||0000-0003-3291-9137
  • Padró, Teresa|||0000-0003-1921-954X
  • García-Arguinzonis, Maisa|||0000-0001-6749-5026
  • Vilahur, Gemma|||0000-0002-2828-8873
  • Miñambres, Inka|||0000-0002-0899-3938
  • Pou, Josep Maria
  • Ybarra, Juan
  • Badimon, Lina|||0000-0002-9162-2459
Diabetic (DM) patients have exacerbated atherosclerosis and high CVD burden. Changes in lipid metabolism, lipoprotein structure, and dysfunctional HDL are characteristics of diabetes. Our aim was to investigate whether serum ApoA-I, the main protein in HDL, was biochemically modified in DM patients. By using proteomic technologies, we have identified a 26 kDa ApoA-I form in serum. MS analysis revealed this 26 kDa form as a novel truncated variant lacking amino acids 1-38, ApoA-IΔ(1-38). DM patients show a 2-fold increase in ApoA-IΔ(1-38) over nondiabetic individuals. ApoA-IΔ(1-38) is found in LDL, but not in VLDL or HDL, with an increase in LDL3 and LDL4 subfractions. To identify candidate mechanisms of ApoA-I truncation, we investigated potentially involved enzymes by in silico data mining, and tested the most probable molecule in an established animal model of diabetes. We have found increased hepatic cathepsin D activity as one of the potential proteases involved in ApoA-I truncation. Cathepsin D-cleaved ApoA-I exhibited increased LDL binding affinity and decreased antioxidant activity against LDL oxidation. In conclusion, we show for the first time: a) presence of a novel truncated ApoA-I form, ApoA-IΔ(1-38), in human serum; b) ApoA-IΔ(1-38) is transported by LDL; c) ApoA-IΔ(1-38) is increased in dense LDL fractions of DM patients; and d) cathepsin D-ApoA-I truncation may lead to ApoA-IΔ(1-38) binding to LDLs, increasing their susceptibility to oxidation and contributing to the high cardiovascular risk of DM patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Lipidomic changes of LDL in overweight and moderately hypercholesterolemic subjects taking phytosterol- and omega-3-supplemented milk

  • Padró, Teresa|||0000-0003-1921-954X
  • Vilahur, Gemma|||0000-0002-2828-8873
  • Sánchez-Hernández, Joan
  • Hernández García, Marta|||0000-0003-1237-298X
  • Antonijoan Arbós, Rosa Ma|||0000-0002-7099-5125
  • Pérez, Antonio|||0000-0001-5528-1143
  • Badimon, Lina|||0000-0002-9162-2459
The benefits of dietary phytosterols (PhySs) and long-chain n-3 PUFA (ω3) have been linked to their effects as cholesterol- and triglyceride (TGL)-lowering agents. However, it remains unknown whether these compounds have further metabolic effects on LDL lipid composition. Here, we studied the effects of PhyS- or ω3-supplemented low-fat milk (milk) on the LDL-lipidome. Overweight and moderately hypercholesterolemic subjects (n = 32) were enrolled in a two-arm longitudinal crossover study. Milk (250 ml/day), enriched with either 1.57 g PhyS or 375 mg ω3 (EPA + DHA), was given to the participants during two sequential 28 day intervention periods. Compared with baseline, PhyS-milk induced a higher reduction in the LDL cholesterol (LDLc) level than ω3-milk. LDL resistance to oxidation was significantly increased after intervention with PhyS-milk. Changes in TGL and VLDL cholesterol were only evident after ω3-milk intake. Lipidomic analysis revealed a differential effect of the PhyS- and ω3-milk interventions on the LDL lipid metabolite pattern. Content in LDL-glycerophospholipids was reduced after PhyS-milk intake, with major changes in phosphatidylcholine (PC) and phosphatidylserine subclasses, whereas ω3-milk induced significant changes in the long-chain polyunsaturated cholesteryl esters and in the ratio PC36:5/lysoPC16:0, associated to a reduced inflammatory activity. In conclusion, daily intake of milk products containing PhyS or ω3 supplements induce changes in the LDL-lipidome that indicate reduced inflammatory and atherogenic effects, beyond their LDLc- and TGL-lowering effects.